|

TU2218 + KEYTRUDA® (Pembrolizumab) Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • TiumBio Co., Ltd.1

Indications

  • Biliary Tract Cancer1
  • Head and Neck Squamous Cell Carcinoma1
  • Solid Tumor1
  • Colorectal Cancer1
  • Cancer1

San Antonio, Texas1 trial

Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

NEXT Oncology

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.